Aptevo Therapeutics (APVO) Stock Price, News & Analysis

Company Overview

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Key Stats

• Today's Range: $1.12 to $1.23
• 50-Day Range: $1.12 to $4.72
• 52-Week Range: $1.12 to $180.19
• Volume: 111,450 shs
• Average Volume: 148,558 shs
• Market Capitalization: $1.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10,952.00
• Consensus Rating: Buy

Aptevo Therapeutics Stock Analysis - MarketRank™

Aptevo Therapeutics scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Aptevo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aptevo Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aptevo Therapeutics are expected to grow in the coming year, from ($15.84) to ($14.49) per share.

Price to Book Value per Share Ratio

Aptevo Therapeutics has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.26% of the float of Aptevo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aptevo Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aptevo Therapeutics has recently increased by 100.67%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aptevo Therapeutics does not currently pay a dividend.

Dividend Growth

Aptevo Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.26% of the float of Aptevo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aptevo Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aptevo Therapeutics has recently increased by 100.67%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.44

News Sentiment

Aptevo Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Aptevo Therapeutics this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for APVO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Aptevo Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.12% of the stock of Aptevo Therapeutics is held by insiders.

Percentage Held by Institutions

Only 8.06% of the stock of Aptevo Therapeutics is held by institutions.

APVO Stock Analysis - Frequently Asked Questions

How have APVO shares performed this year?

Aptevo Therapeutics' stock was trading at $4.31 at the beginning of 2025. Since then, APVO stock has decreased by 74.0% and is now trading at $1.12.
View the best growth stocks for 2025 here.

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) issued its earnings results on Thursday, August, 8th. The biotechnology company reported ($2,286.23) earnings per share for the quarter, topping the consensus estimate of ($2,642.17) by $355.94.

When did Aptevo Therapeutics' stock split?

Aptevo Therapeutics's stock reverse split on Wednesday, March 6th 2024. The 1-44 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Who are Aptevo Therapeutics' major shareholders?

Top institutional investors of Aptevo Therapeutics include Virtu Financial LLC (4.24%) and Concourse Financial Group Securities Inc..
View institutional ownership trends.

How do I buy shares of Aptevo Therapeutics?

Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aptevo Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Alibaba Group (BABA), Plug Power (PLUG) and Micron Technology (MU).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 3/30/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:APVO
• CIK: 1671584
• Web: www.aptevotherapeutics.com
• Phone: (206) 838-0500
• Fax: 206-838-0503
• Employees: 50
• Year Founded: 2016

Price Target and Rating

• Average Stock Price Target: $10,952.00
• High Stock Price Target: $10,952.00
• Low Stock Price Target: $10,952.00
• Potential Upside/Downside: +977,757.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-24,130,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -488.93%
• Return on Assets: -152.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.72
• Quick Ratio: 1.72

Sales & Book Value

• Annual Sales: $3.11 million
• Price / Sales: 0.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.26 per share
• Price / Book: 0.34

Miscellaneous

• Outstanding Shares: 1,459,000
• Free Float: 1,456,000
• Market Cap: $1.63 million
• Optionable: Not Optionable
• Beta: 5.24